NASDAQ · Financial Statements

LB Pharmaceuticals Inc (LBRX) Revenue, Earnings & Financial Statements

$40.30 NASDAQ: LBRX Market Cap $1.30B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

LB Pharmaceuticals Inc most recently reported annual revenue of $0, a net loss of $25.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

LB Pharmaceuticals Inc: net profit was positive in 0 of 4 reported years; the most recent year shows a net loss of $25.0M.

Income Statement — 4 Years (USD millions)

Metric2022202320242025
Revenue$0$0$0$0
Operating Expenses$3.0M$11.0M$65.0M$30.0M
Operating Profit−$3.0M−$11.0M−$65.0M−$30.0M
Other Income−$12.0M$5.0M$2.0M$5.0M
Interest$2.0M$5.0M$0$0
Depreciation$0$0$0$0
Profit Before Tax−$14.0M−$6.0M−$63.0M−$25.0M
Tax rate (%)-0.0%-0.0%0.0%0.0%
Net Profit−$14.0M−$6.0M−$63.0M−$25.0M
EPS−$4.05−$1.77−$17.83−$1.00

Quarterly Results — Last 10 Quarters (USD millions)

MetricMar '24Jun '24Sep '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$0$0$0$0$0
Operating Expenses$17.0M$27.0M$16.0M$6.0M$6.0M$5.0M$14.0M$22.0M$54.0M−$3.0M
Operating Profit−$17.0M−$27.0M−$16.0M−$6.0M−$6.0M−$5.0M−$14.0M−$22.0M−$54.0M$3.0M
Interest$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$16.0M−$28.0M−$14.0M−$5.0M−$5.0M−$4.0M−$11.0M−$19.0M−$52.0M−$59.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%-0.0%0.0%0.0%0.0%
Net Profit−$16.0M−$28.0M−$14.0M−$5.0M−$5.0M−$4.0M−$11.0M−$19.0M−$52.0M−$59.0M
EPS−$4.56−$7.82−$0.63−$20.21−$20.21−$0.14−$0.45−$0.67−$1.71−$1.79

Over the 4 years reported for LB Pharmaceuticals Inc, borrowings decreased from $24.0M in 2022 to $4.0M in 2025, cash stood at $250.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 44.00 times.

Balance Sheet — 4 Years (USD millions)

Metric2022202320242025
Total Assets$21.0M$46.0M$34.0M$313.0M
Current Assets$21.0M$46.0M$29.0M$308.0M
Cash$21.0M$15.0M$23.0M$250.0M
Inventory$0$0$0$0
Receivables$0$0$0$0
Fixed Assets$0$0$4.0M$4.0M
Capital Work in Progress$0$0$0$0
Investments$0$28.0M$5.0M$46.0M
Other Assets$0$0$0$0
Total Liabilities$50.0M$80.0M$128.0M$12.0M
Current Liabilities$0$3.0M$8.0M$7.0M
Borrowings$24.0M$0$4.0M$4.0M
Other Liabilities$26.0M$80.0M$124.0M$8.0M
Equity$0$0$0$0
Reserves−$29.0M−$34.0M−$95.0M$301.0M

For LB Pharmaceuticals Inc, operating cash flow was positive in 0 of 4 reported years; free cash flow in the latest year was negative at $35.0M; free cash flow was positive in 0 of 4 years.

Cash Flow Statement — 4 Years (USD millions)

Metric2022202320242025
Operating Cash Flow−$3.0M−$12.0M−$53.0M−$35.0M
Investing Cash Flow$0−$28.0M$22.0M−$40.0M
Financing Cash Flow−$3.0M−$2.0M−$2.0M$0
Net Cash Flow$20.0M−$6.0M$8.0M$227.0M
Free Cash Flow−$3.0M−$12.0M−$54.0M−$35.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-11.44
FCF Yield-6.47%
Quick Ratio15.08
Interest Coverage—
Return 1Y188.66%
Return 3Y—
Return 5Y—

LB Pharmaceuticals Inc (LBRX) financials — frequently asked questions

What is LB Pharmaceuticals Inc's annual revenue?

LB Pharmaceuticals Inc (LBRX) reported annual revenue of $0 in its most recent fiscal year.

What is LB Pharmaceuticals Inc's net profit?

LB Pharmaceuticals Inc (LBRX) reported a net loss of $25.0M in its most recent fiscal year.

What is LBRX EV/EBITDA?

LB Pharmaceuticals Inc's enterprise value to EBITDA (EV/EBITDA) ratio is -11.44. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
LBRX Overview LBRX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.